IBJNews

Lilly, partner find no Bydureon effect on heart rhythm

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. said an analysis of a 148-patient trial found no evidence that their experimental Bydureon diabetes drug causes prolonged heart rhythms.

The analysis, released in summary form Sunday at the American Diabetes Association annual scientific meeting in San Diego, found the drug “did not affect” a heart rhythm called the QT interval, according to the abstract. The analysis includes data the companies previously submitted to the U.S. Food and Drug Administration.

Last October, the FDA refused to approve Bydureon, a weekly version of Indianapolis-based Lilly and San Diego-based Amylin’s diabetes drug Byetta. The agency asked the two companies and Alkermes of Waltham, Mass., to perform a new study looking at whether high levels of Bydureon can cause an abnormal heart rhythm that may increase the risk of sudden cardiac death. The study results will be available in the second half of this year, said Christian Weyer, senior vice president at Amylin.

The results of the current analysis “are very reassuring,” Weyer said. “Ultimately, we need to await the result of the ongoing study.”

The companies plan to resubmit Bydureon for approval “very shortly” after the ongoing study is completed, he said.

European regulators gave approval to Bydureon a week ago.

In other research from the meeting, the companies reported data from a 121-patient study finding that a once-monthly version of Byetta may produce similar blood sugar control to the weekly version of Bydureon over a 20-week period.

Byetta, a twice-daily injection that has been sold since 2005, generated $710.2 million in sales last year, according to Bloomberg data.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT